Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Non-specific immunosuppression and multiple sclerosis]

B Brochet1

  • 1Service de Neurologie, Hôpital Pellegrin, CHRU de Bordeaux.

Revue Neurologique
|November 11, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers.

Revue neurologique·2025
Same author

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis and related disorders·2020
Same author

SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis.

Journal of neurology·2020
Same author

French validation of the Brief International Cognitive Assessment for Multiple Sclerosis.

Revue neurologique·2020
Same author

Effect of cognitive rehabilitation on neuropsychological and semiecological testing and on daily cognitive functioning in multiple sclerosis: The REACTIV randomized controlled study.

Journal of the neurological sciences·2020
Same author

Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC.

Multiple sclerosis journal - experimental, translational and clinical·2019
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026
See all related articles

Immunosuppression shows partial efficacy in multiple sclerosis (MS) by reducing new lesions and acute episodes. Early, prolonged treatment may modestly slow disease progression, especially in responders.

Area of Science:

  • Neuroimmunology
  • Neurology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Experimental autoimmune encephalitis (EAE) serves as a model for MS, with immunosuppression showing efficacy in EAE.
  • Pathophysiological changes in MS, such as new lesions, are observable via magnetic resonance imaging (MRI).

Purpose of the Study:

  • To evaluate the efficacy of immunosuppression in managing multiple sclerosis.
  • To determine the impact of immunosuppression on disease progression and acute episodes in MS.
  • To assess the effectiveness of immunosuppressive agents like mitoxantrone and Campath.

Main Methods:

  • Analysis of therapeutic trials for progressive forms of multiple sclerosis.
  • Review of evidence on immunosuppression's effects on MRI-detected lesions and clinical outcomes.

Related Experiment Videos

  • Consideration of the limitations of current therapeutic trial methodologies.

    • Main Results:

    • Prolonged immunosuppression appears to modestly slow disease progression in responders, while short-term, high-dose therapy does not.
    • Immunosuppression effectively reduces the number of acute MS episodes and new MRI-detectable lesions.
    • The clinical course of progressive MS is influenced by demyelination and axon loss within existing lesions, not solely new lesion development.

    Conclusions:

    • Immunosuppression offers partial efficacy in multiple sclerosis treatment.
    • Early and prolonged immunosuppressive therapy is favored to maximize benefits, particularly in slowing disease progression.
    • Well-tolerated immunosuppressive treatments are preferred due to the modest effect on overall disease progression.